An interventional study of Quran recital and standard treatment and care in Breast Carcinoma, sponsored by Ardahan University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Ardahan University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 400 studies in Breast Neoplasms with a site in Turkey — 83 open to participants now, 129 under way, 46 of them phase 3. Breast Neoplasms · Turkey.
Among the 400 studies in Breast Neoplasms with a site in Turkey, this one is the 291st largest by enrollment of the 321 interventional ones that give a count, is one of 45 that started in 2025, is one of 184 with no phase, and was the 302nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →83 of the 400 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18+ · Women only · Healthy volunteers
Bursa City Hospital · Sites in Turkey
Ages 18–85 · Women only
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
Ege University · Sites in Turkey
Ages 18+ · Women only
Mucahide Emine Fidancı Kuas · Sites in Turkey
Ages 18–85 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
400 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 36 · Phase 3 98 · Phase 4 5
First in 1996; this study’s year is marked. 45 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 321 interventional studies, 80 across the 79 observational. Of the 247 that completed or were terminated, 67 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 400 have an industry lead sponsor. The 10 most frequent:
Ardahan University is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
Ardahan University has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Breast Neoplasms with a site in Turkey that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 34 to your calendar (.ics) → With an account.
Among the 400 studies in Breast Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate the effect of listening to Qur'an on quality of life and sleep quality in women undergoing chemotherapy for breast cancer. This single-blind randomized controlled trial included 40 women receiving chemotherapy for breast cancer. Participants were assigned using block randomization to either a Qur'an listening group (QLG) or a control group (CG). The QLG listened to Qur'an recitation during chemotherapy sessions, while the CG received standard care only. Data were collected at four time points (T1-T4) using a patient information form, the EORTC QLQ-C30, and the Pittsburgh Sleep Quality Index (PSQI). Analyses were performed using SPSS 26. Across four measurements, the QLG showed significant improvements in all functional domains of the EORTC QLQ-C30 and significant reductions in most symptom domains (p \< .05). No comparable changes were observed in the CG. Overall quality of life increased progressively from T1 to T4 in the QLG, with significant between-group differences emerging at T3 and T4. PSQI total scores decreased significantly in the QLG at T3 and T4 (p \< .001), whereas no clinically meaningful improvement occurred in the CG. At T4, PSQI scores were significantly lower in the QLG than in the CG (p \< .001). Listening to the Qur'an during chemotherapy significantly improves quality of life and sleep quality in women with breast cancer. This non-invasive, low-cost intervention may be integrated into supportive nursing care in oncology settings in accordance with patients' preferences.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Quran listening
Behavioral: Quran recital
standard treatment and care
Other: standard treatment and care
standard treatment and care
Also known as: standard treatment and care
standard treatment and care
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Version 3.0
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Version 3.0, will be used to assess quality of life. The first 28 items are scored from 1 (not at all) to 4 (very much), while items 29 and 30 are scored from 1 (very poor) to 7 (excellent). Higher scores on the functional scales and Global Health Status/Quality of Life scale indicate better functioning and quality of life, whereas higher scores on the symptom scales and single-item measures indicate greater symptom burden.
Time frame: From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.
Pittsburgh Sleep Quality Index (PSQI)
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The scale consists of seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 to 3. The total PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality. A global PSQI score greater than 5 indicates poor sleep quality.
Time frame: From registration to the end of treatment at Week 12, with four measurements conducted during the first, second, third, and final chemotherapy protocols.
Plan to share: No — Individual participant data cannot be shared with third parties in order to protect personal data.
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Jan 2026, 9 months.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 9 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Apr 2026 → Jan 2026 and completion Apr 2026 → Jan 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ardahan University